What is the recommended dosing schedule, contraindications, and monitoring for Prevera (medroxyprogesterone acetate) in a reproductive‑age woman with cyclic pelvic pain and premenstrual mastalgia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Prevera (Medroxyprogesterone Acetate) for Cyclic Pelvic Pain and Premenstrual Mastalgia

For a reproductive-age woman with cyclic pelvic pain and premenstrual mastalgia, medroxyprogesterone acetate (MPA) should be prescribed at 5-10 mg daily for 5-10 days per cycle (days 16-25), with reassessment every 3-6 months to determine continued need for therapy. 1

Dosing Schedule

For Cyclic Pelvic Pain

  • Start with 5-10 mg daily for 5-10 days beginning on day 16 of the menstrual cycle 1
  • The 10-day protocol (days 16-25) is more effective than the 15-day protocol for regulating menstrual cycles and stopping abnormal bleeding 2
  • For pelvic congestion syndrome specifically, higher doses (30 mg daily for 6 months) have shown efficacy in reducing pain by 75% when ovarian suppression is achieved 3
  • Progestin withdrawal bleeding typically occurs 3-7 days after discontinuing therapy 1

For Premenstrual Mastalgia

MPA is NOT recommended for mastalgia treatment. Despite theoretical rationale, a randomized controlled trial demonstrated that 20 mg/day MPA during the luteal phase provided no better pain relief than placebo 4. Paradoxically, depot MPA (DMPA) at contraceptive doses actually reduces mastalgia prevalence from 21% to 9% compared to controls 5, suggesting that continuous ovarian suppression—not cyclic supplementation—may be beneficial if hormonal therapy is pursued.

Contraindications (Absolute)

Before prescribing, you must exclude:

  • Pregnancy (obtain pregnancy test; MPA increases risk of minor birth defects if used in first 4 months) 1
  • Unusual vaginal bleeding (rule out malignancy with endometrial sampling if indicated) 1
  • Current or history of breast cancer or other hormone-sensitive malignancies 1
  • Active or history of thromboembolic disease (stroke, MI, DVT/PE) 1
  • Active liver disease 1
  • Known hypersensitivity to MPA 1

Monitoring Requirements

Initial Assessment

  • Confirm diagnosis of cyclic pelvic pain etiology (endometriosis, pelvic congestion, ovulatory dysfunction)
  • Exclude organic pathology through appropriate imaging/laparoscopy
  • Baseline pregnancy test
  • Document baseline pain severity using validated scales (VAS or numerical rating scale)

Ongoing Monitoring

  • Reassess every 3-6 months to determine if treatment remains necessary 1
  • Monitor for breakthrough bleeding (common side effect; occurs in significant proportion of users) 1
  • Annual pelvic exam and breast exam 1
  • If breakthrough bleeding persists, consider NSAIDs for 5-7 days as first-line management 6

Red Flags Requiring Immediate Evaluation

  • New breast lumps
  • Unusual vaginal bleeding patterns
  • Sudden severe headaches
  • Visual changes or speech difficulties
  • Severe chest or leg pain (possible thromboembolism)
  • Signs of pregnancy 1

Clinical Algorithm

  1. Confirm eligibility: Rule out contraindications, obtain pregnancy test
  2. Start low: Begin with 5 mg daily on days 16-25 of cycle 1
  3. Titrate if needed: Increase to 10 mg daily if inadequate response after 2-3 cycles
  4. Reassess at 3 months: Evaluate pain reduction using standardized scales
  5. Continue if effective: Maintain lowest effective dose with 3-6 month check-ins 1
  6. Discontinue if ineffective: If no improvement after 3 cycles, consider alternative therapies

Important Caveats

For mastalgia specifically: Do not use cyclic MPA based on high-quality evidence showing no benefit over placebo 4. If considering hormonal therapy for mastalgia, depot DMPA for continuous ovarian suppression shows more promise 5, though this is off-label for mastalgia treatment.

For pelvic pain: The evidence supports MPA effectiveness primarily when pain is related to endometriosis 7, 8 or pelvic congestion with demonstrable ovarian suppression 3. If pain persists despite adequate trial, reconsider the diagnosis.

Bone density concerns: While relevant for depot formulations with prolonged use, oral cyclic MPA at these doses and durations has minimal bone density impact 9.

Bleeding irregularities: These are the most common side effect. Counsel patients that irregular bleeding, spotting, or amenorrhea may occur and does not indicate treatment failure 1. NSAIDs for 5-7 days can manage breakthrough bleeding 6.

Related Questions

How should progesterone be used to manage pelvic pain and heaviness as a temporary measure while arranging definitive treatment?
In a 50‑year‑old woman taking medroxyprogesterone acetate 10 mg daily for five days, how many days after the last dose should the menstrual bleeding stop?
In a reproductive‑age woman treated with prevera (medroxyprogesterone acetate) for cyclic pelvic pain and premenstrual mastalgia, does the medication cause bleeding or spotting?
For a 50-year-old woman receiving her scheduled Depo‑Provera injection who has been off sertraline 50 mg and buspirone 15 mg for about five weeks, can both medications be restarted simultaneously, and what initial dosing should be used?
What are alternative treatments to medroxyprogesterone acetate (Provera) for heavy menstrual bleeding (menorrhagia) in a patient taking topiramate?
What oral glutathione dose should be given to raise the patient's glutathione levels, and can N‑acetylcysteine (NAC) be used as an alternative?
What patient teaching should be provided for a 16-year-old with ADHD who is prescribed guanfacine?
What is the comprehensive pediatric and medical information on typhoid fever?
In a reproductive‑age woman treated with prevera (medroxyprogesterone acetate) for cyclic pelvic pain and premenstrual mastalgia, does the medication cause bleeding or spotting?
What are the recommended conservative management strategies for hemorrhoids and an anal fissure?
I have a dry, nagging cough that makes it difficult to speak; should I use a Medrol (methylprednisolone) dose pack or 40 mg daily for five days?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.